North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2024 - 2029)

North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis

The North America Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 4.02 billion in 2024, and is expected to reach USD 4.20 billion by 2029, growing at a CAGR of 0.9% during the forecast period (2024-2029).

Type 2 diabetes emerged as one of the most important and common risk factors for COVID-19 mortality. The risk of COVID-19 mortality was twice as high in people with type 2 diabetes as in those without; studies showed an association between hyperglycemia and increased COVID-19-related mortality in people with type 2 diabetes. The DPP-4 inhibitors were hypothesized to potentially modify the biological activity of various substrates involved in the immune response to the infection, suggesting potential benefit.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lowers high blood glucose levels and treat type 2 diabetes. Dipeptidyl-peptidase 4 inhibitors have glucose regulatory actions by prolonging the effects of GLP-1 and GIP, ultimately increasing glucose-mediated insulin secretion and suppressing glucagon secretion. Besides the glucose-lowering properties of DPP4 inhibitors, emerging evidence suggests that incretin-based therapies may also positively impact inflammation, cardiovascular and hepatic health, sleep, and the central nervous system.

According to Diabetes Canada, new 2022 figures show the continued rising trend of diabetes rates in Canada with no signs of leveling or decreasing. Diabetes continues to affect more Canadians than ever before. The new diabetes figures show a steady, continued increase in diabetes in the country, with 11.7 million Canadians living with diabetes or prediabetes. More than 5.7 million Canadians are living with diagnosed diabetes, and people living with diabetes or prediabetes, which, if left unmanaged, can develop into type 2 diabetes.

The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, developing pathways for a substantial increase in access to insulin, promoting convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improving diabetes monitoring and surveillance. Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.

Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.

North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Segmentation

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating type 2 diabetes. They help to control glycemia by increasing the levels of active incretins. The North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Is Segmented into Drugs and Geography. The report offers the market size in value terms in USD for all the abovementioned segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.